Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

Platelet-Rich Plasma Extract Prevents Pulmonary Edema through Angiopoietin-Tie2 Signaling

(2015) Tadanori Mammoto et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Angiogenic and growth factors in gastric cancer

(2015) Susanne Blank et al.   JOURNAL OF SURGICAL RESEARCH

A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib

(2014) Subhajit Roy et al.   Anti-Cancer Agents in Medicinal Chemistry

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

(2014) Hanna Sallinen et al.   BMC CANCER

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

(2014) Anna R Kwilas et al.   Journal of Translational Medicine

E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-κB modulation

(2014) Zijia Ren et al.   Molecular Cancer

Circulating Ang-2 mRNA Expression Levels: Looking Ahead to a New Prognostic Factor for NSCLC

(2014) Ana L. Coelho et al.   PLoS One

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

(2014) B. Farsaci et al.   Cancer Immunology Research

Attacking malignant cells that survive therapy

(2014) James W Hodge et al.   OncoImmunology

Clinical Significance of Serum Angiopoietin-1 in Malignant Peritoneal Mesothelioma

(2013) Koji Mikami et al.   CANCER INVESTIGATION

Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics

(2013) James H. Finke et al.   CANCER JOURNAL

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Angiopoietin signaling in the vasculature

(2013) Lauri Eklund et al.   EXPERIMENTAL CELL RESEARCH

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

(2013) James W. Hodge et al.   INTERNATIONAL JOURNAL OF CANCER

Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression

(2013) Sofia R. Gameiro et al.   PLoS One

Overcoming Resistance to Antiangiogenic Therapies

(2012) S. Tejpar et al.   ONCOLOGIST

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

Immunomodulatory effects of anti-angiogenic drugs

(2011) A Heine et al.   LEUKEMIA

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?

(2011) Katrien De Bock et al.   Nature Reviews Clinical Oncology

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integration of Host-Related Signatures with Cancer Cell-Derived Predictors for the Optimal Management of Anticancer Chemotherapy

(2010) L. Zitvogel et al.   CANCER RESEARCH

A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma

(2010) C. Tabata et al.   EUROPEAN RESPIRATORY JOURNAL

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels

(2009) Beverly L. Falcón et al.   AMERICAN JOURNAL OF PATHOLOGY

Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium

(2009) H. T. Yuan et al.   MOLECULAR AND CELLULAR BIOLOGY

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH